a nurse is caring for a client who has a new prescription for valproic acid the nurse should instruct the client that while taking this medication he

ATI RN

ATI Pharmacology Test Bank

1. A client has a new prescription for Valproic Acid. The client should be informed that which of the following laboratory tests need to be completed periodically? (Select all that apply.)

A. Thrombocyte count.
B. Hematocrit.
C. Amylase.
D. Liver function tests.

Correct answer: A

Rationale: Valproic acid can lead to thrombocytopenia, making it essential to monitor the client's thrombocyte count periodically. Additionally, valproic acid can cause pancreatitis, necessitating the monitoring of amylase levels. Furthermore, valproic acid carries a risk of hepatotoxicity, requiring regular monitoring of liver function tests.

2. A client is starting therapy with filgrastim. Which of the following adverse effects should the nurse instruct the client to monitor?

A. Bone pain
B. Constipation
C. Tinnitus
D. Dry mouth

Correct answer: A

Rationale: When a client is starting therapy with filgrastim, monitoring for bone pain is essential. Filgrastim can lead to increased bone marrow activity, resulting in bone pain as a common adverse effect. Instructing the client to monitor and report any bone pain promptly can help in managing this side effect effectively.

3. A client is starting therapy with docetaxel. Which of the following findings should the nurse instruct the client to report?

A. Flushing
B. Dyspnea
C. Hyperglycemia
D. Tinnitus

Correct answer: B

Rationale: The correct answer is B: Dyspnea. The nurse should instruct the client to report dyspnea because it can indicate pulmonary toxicity, a serious adverse effect of docetaxel. Dyspnea may be a sign of a potentially life-threatening condition that the healthcare provider needs to address promptly. Flushing (Choice A) is not typically associated with docetaxel therapy. Hyperglycemia (Choice C) is also not a common side effect of docetaxel. Tinnitus (Choice D) is not a usual finding with docetaxel and is not a priority over potential pulmonary toxicity indicated by dyspnea.

4. Which of the following is not related to drug toxicity of Atenolol?

A. CHF
B. Tachycardia
C. AV block
D. Sedative appearance

Correct answer: B

Rationale: Atenolol, a beta-blocker, is not typically associated with tachycardia. Instead, drug toxicity of Atenolol is more commonly linked to bradycardia due to its beta-blocking effects on the heart's electrical conduction system. Symptoms of Atenolol toxicity may include heart failure (CHF), AV block, and a sedative appearance, but not tachycardia.

5. What is the expected pharmacological action of propranolol?

A. Block stimulation of beta1 receptors
B. Alter water and electrolyte transport in the large intestine
C. Block stimulation of beta2 receptors
D. Both A and C are correct

Correct answer: D

Rationale: Propranolol exerts its pharmacological action by blocking stimulation of both beta1 and beta2 receptors. By doing so, it leads to decreased heart rate and blood pressure. Therefore, both options A and C are correct as propranolol affects both types of beta receptors. Choice B is incorrect as propranolol does not alter water and electrolyte transport in the large intestine.